Alisporivir

Alisporivir, bir siklofilin inhibitörüdür.^[1] Yapısı siklosporini andırır ve siklosporinden sentezlenir.

Siklofilin A'yı inhibe eder.^[2] Alisporivir immünosupresif değildir.^[3]

Hepatit C tedavisinde potansiyel kullanım için araştırılmaktadır.^[4]^[5] Duchenne musküler distrofisi^[1] için de araştırılmıştır ve Alzheimer hastalığında terapötik potansiyele sahip olabilir.^[6]

Alisporivir, Şubat 2010'dan bu yana Japonya için Debiopharm ve dünyanın geri kalanı için Novartis tarafından geliştirilmektedir.

Kaynakça[değiştir | kaynağı değiştir]

^ ^a ^b "Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy". British Journal of Pharmacology. 155 (4): 574-84. October 2008. doi:10.1038/bjp.2008.285. PMC 2579666 $2. PMID 18641676.
^ Gallay, PA; Lin, K. (15 Şubat 2013). "Profile of alisporivir and its potential in the treatment of hepatitis C". Drug Design, Development and Therapy. 7: 105-115. doi:10.2147/DDDT.S30946. PMC 3578503 $2. PMID 23440335.
^ "Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent". Antimicrob. Agents Chemother. 52 (4): 1302-17. April 2008. doi:10.1128/AAC.01324-07. PMC 2292519 $2. PMID 18212100.
^ "The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro". Hepatology. 43 (4): 761-70. April 2006. doi:10.1002/hep.21102. PMID 16557546.
^ "Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with Specifically Targeted Antiviral Therapy for HCV (STAT-C) inhibitors". Antimicrobial Agents and Chemotherapy. 53 (3): 967-76. December 2008. doi:10.1128/AAC.00939-08. PMC 2650540 $2. PMID 19104013.
^ "USC study reveals potential new treatment target for Alzheimer's disease | Keck School of Medicine of USC" (İngilizce). 14 Haziran 2021 tarihinde kaynağından arşivlendi. Erişim tarihi: 16 Haziran 2021.

[pmid18641676-1] "Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy". British Journal of Pharmacology. 155 (4): 574-84. October 2008. doi:10.1038/bjp.2008.285. PMC 2579666 $2. PMID 18641676.

[2] Gallay, PA; Lin, K. (15 Şubat 2013). "Profile of alisporivir and its potential in the treatment of hepatitis C". Drug Design, Development and Therapy. 7: 105-115. doi:10.2147/DDDT.S30946. PMC 3578503 $2. PMID 23440335.

[pmid18212100-3] "Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent". Antimicrob. Agents Chemother. 52 (4): 1302-17. April 2008. doi:10.1128/AAC.01324-07. PMC 2292519 $2. PMID 18212100.

[pmid16557546-4] "The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro". Hepatology. 43 (4): 761-70. April 2006. doi:10.1002/hep.21102. PMID 16557546.

[pmid19104013-5] "Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with Specifically Targeted Antiviral Therapy for HCV (STAT-C) inhibitors". Antimicrobial Agents and Chemotherapy. 53 (3): 967-76. December 2008. doi:10.1128/AAC.00939-08. PMC 2650540 $2. PMID 19104013.

[6] "USC study reveals potential new treatment target for Alzheimer's disease | Keck School of Medicine of USC" (İngilizce). 14 Haziran 2021 tarihinde kaynağından arşivlendi. Erişim tarihi: 16 Haziran 2021.

[1]

[2]

[3]

[4]

[5]

[6]